{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-088622","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.165272+00:00","generated_at":"2026-06-24T01:24:44.072543+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TELA Bio Q2 revenue $10.4M (+38% YoY); FY2022 guidance $42-45M","bullets":["Q2 revenue of $10.4M, up 38% YoY; OviTex revenue +22%, OviTex PRS +87%.","Net loss widened to $12.7M from $8.3M; operating loss $10.2M vs $7.3M.","FY2022 revenue guidance $42-45M (43-53% growth); COVID could impact.","Cash $27.7M at June 30; secured up to $50M debt facility from MidCap Financial.","Entered GPO contract with Premier Inc. covering ~4,400 hospitals, effective October 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-088622","json":"https://secwatch.observer/filing/0001104659-22-088622.json","markdown":"https://secwatch.observer/filing/0001104659-22-088622.md","text":"https://secwatch.observer/filing/0001104659-22-088622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922088622/0001104659-22-088622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922088622/tm2223031d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:24:44.072543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}